The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 26985317 |
20 |
Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5. |
Bristol-Myers Squibb Research & Development |
| 26897089 |
39 |
Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists. |
Vitae Pharmaceuticals |
| 26819660 |
82 |
SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious ROR¿ Inhibitor. |
Central Pharmaceutical Research Institute |
| 26683992 |
25 |
2-Chloro-4-[[(1R,2R)-2-hydroxy-2-methyl-cyclopentyl]amino]-3-methyl-benzonitrile: A Transdermal Selective Androgen Receptor Modulator (SARM) for Muscle Atrophy. |
Eli Lilly |
| 26407012 |
80 |
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist. |
Astrazeneca |
| 26218343 |
76 |
Indole Glucocorticoid Receptor Antagonists Active in a Model of Dyslipidemia Act via a Unique Association with an Agonist Binding Site. |
Eli Lilly |
| 25978072 |
53 |
Synthesis and Biological Evaluation of Cyclopentaquinoline Derivatives as Nonsteroidal Glucocorticoid Receptor Antagonists. |
TBA |
| 25879485 |
60 |
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. |
Seragon Pharmaceuticals |
| 25941555 |
75 |
Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists. |
Merck Research Laboratories |
| 25706100 |
65 |
2-Aryl-3-methyloctahydrophenanthrene-2,3,7-triols as potent dissociated glucocorticoid receptor agonists. |
TBA |
| 25593098 |
17 |
Development of 1,3-diphenyladamantane derivatives as nonsteroidal progesterone receptor antagonists. |
Tokyo Medical And Dental University |
| 25121964 |
18 |
3-alkoxy-pyrrolo[1,2-b]pyrazolines as selective androgen receptor modulators with ideal physicochemical properties for transdermal administration. |
Novartis Institutes For Biomedical Research |
| 24980053 |
153 |
Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists. |
Bristol-Myers Squibb |
| 25516791 |
177 |
Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate. |
Boehringer Ingelheim Pharmaceuticals |
| 25305688 |
41 |
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORß and ROR¿t. |
Phenex Pharmaceuticals |
| 25187277 |
136 |
Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists. |
Takeda Pharmaceutical |
| 24755427 |
107 |
The discovery of potent and selective non-steroidal glucocorticoid receptor modulators, suitable for inhalation. |
Astrazeneca |
| 24738581 |
81 |
Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist. |
Pfizer |
| 24630411 |
38 |
Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series. |
Merck Research Laboratories |
| 24656565 |
73 |
Discovery of a potent and dissociated non-steroidal glucocorticoid receptor agonist containing an alkyl carbinol pharmacophore. |
Boehringer Ingelheim Pharmaceuticals |
| 24506830 |
91 |
Identification of highly efficacious glucocorticoid receptor agonists with a potential for reduced clinical bone side effects. |
Boehringer Ingelheim Pharmaceuticals |
| 24446728 |
30 |
Glucocorticoid receptor modulators informed by crystallography lead to a new rationale for receptor selectivity, function, and implications for structure-based design. |
Eli Lilly |
| 24239189 |
85 |
Substituted phenyl as a steroid A-ring mimetic: providing agonist activity to a class of arylsulfonamide nonsteroidal glucocorticoid ligands. |
Boehringer Ingelheim Pharmaceuticals |
| 24215891 |
107 |
Function-regulating pharmacophores in a sulfonamide class of glucocorticoid receptor agonists. |
Boehringer Ingelheim Pharmaceuticals |
| 24157365 |
23 |
Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists. |
Pfizer |
| 23953070 |
146 |
Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists. |
Ironwood Pharmaceuticals |
| 23916594 |
92 |
Synthesis and structure-activity relationships of novel indazolyl glucocorticoid receptor partial agonists. |
Bristol-Myers Squibb |
| 23958516 |
61 |
Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists. |
Takeda Pharmaceutical |
| 23777778 |
101 |
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists. |
Merck Research Laboratories |
| 16678409 |
10 |
Array synthesis of progesterone receptor antagonists: 3-aryl-1,2-diazepines. |
Glaxosmithkline |
| 22280402 |
12 |
"True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer. |
Trinity College |
| 21129964 |
28 |
Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist. |
Merck Research Laboratories |
| 20727743 |
64 |
Discovery of quinolines as selective glucocorticoid receptor agonists. |
Bayer Schering Pharma |
| 20469868 |
176 |
Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists. |
Glaxosmithkline |
| 20202837 |
51 |
The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist. |
Medicines Research Centre |
| 19664922 |
35 |
2-Amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]thieno[2,3-b]pyridine derivatives as selective progesterone receptor agonists. |
Glaxosmithkline |
| 18952422 |
5 |
The first X-ray crystal structure of the glucocorticoid receptor bound to a non-steroidal agonist. |
Glaxosmithkline |
| 11150172 |
8 |
Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. |
Schering |
| 23079530 |
27 |
Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides. |
Pfizer |
| 22897611 |
2 |
Discovery of diarylhydantoins as new selective androgen receptor modulators. |
Galapagos, Parc Biocitech |
| 22866979 |
19 |
Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy. |
Pfizer |
| 21073190 |
135 |
Dimethyl-diphenyl-propanamide Derivatives As Nonsteroidal Dissociated Glucocorticoid Receptor Agonists. |
Bristol-Myers Squibb |
| 20735001 |
145 |
Nonsteroidal dissociated glucocorticoid agonists containing azaindoles as steroid A-ring mimetics. |
Boehringer Ingelheim Pharmaceuticals |
| 20672822 |
108 |
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. |
Pfizer |
| 20672820 |
92 |
Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists. |
Pfizer |
| 20638844 |
25 |
1-Methyl-1H-pyrrole-2-carbonitrile containing tetrahydronaphthalene derivatives as non-steroidal progesterone receptor antagonists. |
Pfizer |
| 20510622 |
142 |
Aromatic beta-amino-ketone derivatives as novel selective non-steroidal progesterone receptor antagonists. |
Chinese Academy Of Sciences |
| 20355713 |
3 |
Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget. |
University Of Illinois |
| 19863083 |
25 |
The lecanindoles, nonsteroidal progestins from the terrestrial fungus Verticillium lecanii 6144. |
Wyeth Research |
| 20149664 |
4 |
Synthesis, in vitro progesterone receptors affinity of gadolinium containing mifepristone conjugates and estimation of binding sites in human breast cancer cells. |
University Of Quebec At Trois-Rivieres |
| 20047280 |
174 |
Novel synthesis of the hexahydroimidazo[1,5b]isoquinoline scaffold: application to the synthesis of glucocorticoid receptor modulators. |
Bristol-Myers Squibb |
| 19217285 |
32 |
Synthesis and SAR study of novel pseudo-steroids as potent and selective progesterone receptor antagonists. |
Johnson And Johnson Pharmaceutical Research And Development |
| 19321341 |
101 |
Discovery of novel dihydro-9,10-ethano-anthracene carboxamides as glucocorticoid receptor modulators. |
Bristol-Myers Squibb |
| 19216549 |
49 |
Syntheses and antigestagenic activity of mifepristone derivatives. |
University Of Graz |
| 18722119 |
55 |
1,5-Dihydro-benzo[e][1,4]oxazepin-2(1H)-ones containing a 7-(5'-cyanopyrrol-2-yl) group as nonsteroidal progesterone receptor modulators. |
Wyeth Research |
| 18504132 |
51 |
7-aryl 1,5-dihydro-benzo[e][1,4]oxazepin-2-ones and analogs as non-steroidal progesterone receptor antagonists. |
Wyeth Research |
| 18513967 |
103 |
Discovery of nonsteroidal glucocorticoid receptor ligands based on 6-indole-1,2,3,4-tetrahydroquinolines. |
Ligand Pharmaceuticals |
| 18032610 |
4 |
Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. |
Ligand Pharmaceuticals |
| 18318463 |
53 |
Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348). |
Wyeth Research |
| 18243712 |
44 |
11-(pyridinylphenyl)steroids--a new class of mixed-profile progesterone agonists/antagonists. |
Nv Organon |
| 17855092 |
18 |
Synthesis and identification of novel 11beta-aryl-4',5'-dihydrospiro[estra-4,9-diene-17beta,4'-oxazole] analogs with dissociated antiprogesterone activities. |
Rti International |
| 17258455 |
22 |
Discovery of novel phosphorus-containing steroids as selective glucocorticoid receptor antagonist. |
Johnson & Johnson Pharmaceutical Research & Development |
| 17692519 |
108 |
Identification of dissociated non-steroidal glucocorticoid receptor agonists. |
Boehringer Ingelheim Pharmaceuticals |
| 17317167 |
50 |
Parallel synthesis and SAR study of novel oxa-steroids as potent and selective progesterone receptor antagonists. |
Johnson And Johnson Pharmaceutical Research And Development |
| 17118655 |
73 |
Alpha-methyltryptamine sulfonamide derivatives as novel glucocorticoid receptor ligands. |
Boehringer Ingelheim Pharmaceuticals |
| 17169557 |
20 |
Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists. |
Johnson And Johnson Pharmaceutical Research And Development |
| 17181172 |
94 |
Quinol-4-ones as steroid A-ring mimetics in nonsteroidal dissociated glucocorticoid agonists. |
Boehringer Ingelheim Pharmaceuticals |
| 16250653 |
22 |
Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study. |
Universit£ |
| 16112571 |
93 |
Trifluoromethyl group as a pharmacophore: effect of replacing a CF3 group on binding and agonist activity of a glucocorticoid receptor ligand. |
Boehringer Ingelheim Pharmaceuticals |
| 15771445 |
22 |
Binding thermodynamics as a tool to investigate the mechanisms of drug-receptor interactions: thermodynamics of cytoplasmic steroid/nuclear receptors in comparison with membrane receptors. |
University Of Ferrara |
| 15293993 |
172 |
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes. |
Abbott Laboratories |
| 15261265 |
38 |
Synthesis, activity, metabolic stability, and pharmacokinetics of glucocorticoid receptor modulator-statin hybrids. |
Abbott Laboratories |
| 12238914 |
48 |
6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin- 2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists. |
Women'S Health Research Institute |
| 12036351 |
31 |
Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. |
Pfizer |
| 10212133 |
93 |
5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification. |
Ligand Pharmaceuticals |
| 9484511 |
111 |
Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. |
Ligand Pharmaceuticals |
| 9464361 |
48 |
5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents. |
Ligand Pharmaceuticals |
| 9719599 |
18 |
Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore. |
Ligand Pharmaceuticals |
| 9667968 |
18 |
Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists. |
Ligand Pharmaceuticals |
| 8627601 |
169 |
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether. |
Ligand Pharmaceuticals |
| 8523400 |
26 |
Nonsteroidal progesterone receptor ligands. 2. High-affinity ligands with selectivity for bone cell progesterone receptors. |
R. W. Johnson Pharmaceutical Research Institute |
| 15081005 |
30 |
Novel pyrrole-containing progesterone receptor modulators. |
Wyeth Research |
| 15080982 |
122 |
Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists. |
Abbott Laboratories |
| 12657271 |
71 |
Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists. |
Wyeth Research |
| 12781198 |
108 |
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore. |
Ligand Pharmaceuticals |
| 12781197 |
59 |
Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators. |
Ligand Pharmaceuticals |
| 11859003 |
63 |
Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines. |
Wyeth Research |
| 11591515 |
42 |
Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones. |
Wyeth-Ayerst Research |
| 10743938 |
103 |
Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines. |
Ligand Pharmaceuticals |
| 9873735 |
111 |
5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators. |
Ligand Pharmaceuticals |
| 22260770 |
12 |
Synthesis and antihormonal properties of novel 11ß-benzoxazole-substituted steroids. |
Research Triangle Institute |
| 22197391 |
44 |
Steroidal C-21 heteroaryl thioethers (Part 2): discovery of orally bioavailable selective glucocorticoid receptor modulators (dissociated steroids). |
Merck Research Laboratories |
| 22104142 |
9 |
Lead diversification. Application to existing drug molecules: mifepristone 1 and antalarmin 8. |
Pfizer |
| 22074142 |
89 |
Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists. |
Takeda Pharmaceutical |
| 21963986 |
162 |
Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophores. |
Boehringer Ingelheim Pharmaceuticals |
| 21899328 |
244 |
Azaxanthene based selective glucocorticoid receptor modulators: design, synthesis, and pharmacological evaluation of (S)-4-(5-(1-((1,3,4-thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and its methylene homologue (BMS-791 |
Bristol-Myers Squibb |
| 21916484 |
41 |
6-arylcoumarins as novel nonsteroidal type progesterone antagonists: an example with receptor-binding-dependent fluorescence. |
Ochanomizu University |
| 21324689 |
74 |
Nonsteroidal 2,3-dihydroquinoline glucocorticoid receptor agonists with reduced PEPCK activation. |
Ligand Pharmaceuticals |
| 21349714 |
118 |
Tetrahydroquinolin-3-yl carbamate glucocorticoid receptor agonists with reduced PEPCK activation. |
Ligand Pharmaceuticals |
| 21316964 |
108 |
Discovery of orally available tetrahydroquinoline-based glucocorticoid receptor agonists. |
Ligand Pharmaceuticals |
| 24900290 |
7 |
Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140 |
TBA |
| 24900294 |
72 |
Novel 3-Aryl Indoles as Progesterone Receptor Antagonists for Uterine Fibroids |
TBA |
| 21247762 |
13 |
Synthesis, modification, and evaluation of (R)-de-O-methyllasiodiplodin and analogs as nonsteroidal antagonists of mineralocorticoid receptor. |
Chinese Academy Of Sciences |
| 21115247 |
64 |
Tetrahydroquinoline glucocorticoid receptor agonists: discovery of a 3-hydroxyl for improving receptor selectivity. |
Ligand Pharmaceuticals |
| 20638278 |
145 |
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. |
Phenex Pharmaceuticals |
| 20462217 |
17 |
Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery. |
Pfizer |
| 20430618 |
21 |
Optimisation of a pyrazole series of progesterone antagonists; Part 1. |
Pfizer |
| 20408553 |
27 |
Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. |
Pfizer |
| 19926282 |
136 |
Improving the developability profile of pyrrolidine progesterone receptor partial agonists. |
Glaxosmithkline |
| 19864132 |
26 |
5-Aryl indanones and derivatives as non-steroidal progesterone receptor modulators. |
Wyeth Research |
| 19616429 |
32 |
Discovery of orally active, pyrrolidinone-based progesterone receptor partial agonists. |
Glaxosmithkline |
| 19595590 |
49 |
Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists. |
Glaxosmithkline |
| 19606870 |
53 |
Design, synthesis, and biological evaluation of 16-substituted 4-azasteroids as tissue-selective androgen receptor modulators (SARMs). |
Merck Research Laboratories |
| 19376703 |
71 |
Synthesis and SAR of amino acid-derived heterocyclic progesterone receptor full and partial agonists. |
Glaxosmithkline |
| 19239259 |
66 |
Octahydrophenanthrene-2,7-diol analogues as dissociated glucocorticoid receptor agonists: discovery and lead exploration. |
Pfizer |
| 18691892 |
52 |
Discovery of betamethasone 17alpha-carbamates as dissociated glucocorticoid receptor modulators in the rat. |
Merck Research Laboratories |
| 18586498 |
47 |
Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton. |
The University Of Tokyo |
| 18553958 |
28 |
A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline. |
Ligand Pharmaceuticals |
| 18226526 |
32 |
SAR study of 2,3,4,14b-tetrahydro-1H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepines as progesterone receptor agonists. |
Nv Organon |
| 18038968 |
26 |
(S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor. |
Eli Lilly |
| 17764935 |
32 |
Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production. |
Pfizer |
| 17703938 |
55 |
Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones. |
Ligand Pharmaceuticals |
| 17681796 |
21 |
5-(3-Cyclopentyl-2-thioxo-2,3-dihydro-1H-benzimidazol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile: A novel, highly potent, selective, and orally active non-steroidal progesterone receptor agonist. |
Wyeth Research |
| 17587578 |
45 |
Discovery and optimization of novel, non-steroidal glucocorticoid receptor modulators. |
Argenta Discovery |
| 17553679 |
148 |
5(Z)-benzylidene-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-1-aza-6-oxa-chrysenes as non-steroidal glucocorticoid receptor modulators. |
Ligand Pharmaceuticals |
| 17027272 |
26 |
SAR studies of 6-(arylamino)-4,4-disubstituted-1-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-ones as progesterone receptor antagonists. |
Wyeth Research |
| 16078826 |
7 |
Synthesis and structure-activity relationship of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective nonsteroidal progesterone receptor agonist tanaproget. |
Women'S Health Research Institute |
| 15978807 |
24 |
SAR studies of 6-aryl-1,3-dihydrobenzimidazol-2-ones as progesterone receptor antagonists. |
Wyeth Research |
| 15911283 |
62 |
Novel ketal ligands for the glucocorticoid receptor: in vitro and in vivo activity. |
Merck Research Laboratories |
| 15189034 |
2 |
Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. |
Glaxosmithkline |
| 15081010 |
66 |
Discovery of novel nonsteroidal glucocorticoid receptor modulators. |
Abbott Laboratories |
| 15026058 |
61 |
Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators. |
Abbott Laboratories |
| 12954062 |
140 |
5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators. |
Ligand Pharmaceuticals |
| 12657272 |
47 |
Novel 5-aryl-1,3-dihydro-indole-2-thiones. potent, orally active progesterone receptor agonists. |
Wyeth Research |
| 12620078 |
132 |
Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines. |
Abbott Laboratories |
| 12419390 |
37 |
New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles. |
Wyeth Research |
| 11728194 |
98 |
Nonsteroidal selective glucocorticoid modulators: the effect of C-5 alkyl substitution on the transcriptional activation/repression profile of 2,5-dihydro-10-methoxy-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines. |
Abbott Laboratories |
| 11520196 |
81 |
Synthesis and characterization of non-steroidal ligands for the glucocorticoid receptor: selective quinoline derivatives with prednisolone-equivalent functional activity. |
Abbott Laboratories |
| 10230628 |
95 |
Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one. |
Ligand Pharmaceuticals |
| 9873612 |
84 |
Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines. |
Ligand Pharmaceuticals |
| 9871534 |
95 |
New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. |
Ligand Pharmaceuticals |
| 9784110 |
81 |
5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists. |
Ligand Pharmaceuticals |
| 9464360 |
145 |
5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists. |
Ligand Pharmaceuticals |
| 8523399 |
11 |
Nonsteroidal progesterone receptor ligands. 1. 3-Aryl-1-benzoyl-1,4,5,6-tetrahydropyridazines. |
R. W. Johnson Pharmaceutical Research Institute |
| 27250740 |
15 |
Electrostatic Control of Isoform Selective Inhibitor Binding in Nitric Oxide Synthase. |
University Of California Irvine |
Search and Browse
